Pliant Therapeutics Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Pliant Therapeutics Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: South SAN Francisco
Headquarters state / province: California
Headquarters country: United States
Fiscal year end: December
Ticker symbol: PLRX
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001746473
EIN: 47-4272481
Wikidata ID: Q97041244

Board of directors

Follow this board

Bernard Coulie · Director · President and CEO
Since 2023
Darren S. Cline · Director
Since 2023
David E. I. Pyott · Director
Since 2023
Flavia Borellini · Director
Since 2026
Gayle A. Crowell · Director
Since 2023
Hoyoung Huh · Director
Since 2023
John T. Curnutte · Director
Since 2023
Katharine Knobil · Director
Since 2023
Robert Iannone · Director
Since 2026
Smital Shah · Director
Since 2023
Steve E. Krognes · Director
Since 2024
Suzanne Louise Bruhn · Director
Since 2023
Thomas A. Mccourt · Director
Since 2023

Chief executives

Bernard Coulie · President and CEO

Dates unknown

Director election results

Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Gayle A. Crowell

59.4%

Board connections

12 of this board's directors also sit on 17 other boards. 16 are in the same sector.

Shared director Other board Same sector +1 more in the list below

Akari Therapeutics plc Same sector
via Hoyoung Huh
Alnylam Pharmaceuticals Inc. Same sector
via David E. I. Pyott
Autolus Therapeutics plc American Depositary Share Same sector
via Robert Iannone
BioMarin Pharmaceutical Inc. Same sector
via David E. I. Pyott
Definium Therapeutics Inc. Same sector
via Suzanne Louise Bruhn
Denali Therapeutics Inc. Same sector
via Steve E. Krognes
Guardant Health Inc. Same sector
via Steve E. Krognes
Hercules Capital Inc.
via Gayle A. Crowell
Ironwood Pharmaceuticals Inc. Same sector
via Thomas A. Mccourt
Korro Bio Inc. Same sector
via Katharine Knobil
LENZ Therapeutics Inc. Same sector
via Smital Shah
Marker Therapeutics Inc. Same sector
via Katharine Knobil
Pyxis Oncology Inc. Same sector
via Darren S. Cline
Revolution Medicines Inc. Same sector
via Flavia Borellini
Septerna Inc. Same sector
via Bernard Coulie
Tarsus Pharmaceuticals Inc. Same sector
via David E. I. Pyott
Travere Therapeutics Inc. Same sector
via Suzanne Louise Bruhn

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $163,620; 4 sales by 4 insiders

Date	Insider	Transaction	Shares	Price	Value
Jan 20, 2026	Cummings Keith Lamont Officer (Chief Financial Officer)	Open-market sale	−24,002	$1.28	$30,723
Jan 20, 2026	Cheung Lily Officer (Chief Human Resource Officer)	Open-market sale	−7,534	$1.28	$9,644
Jan 20, 2026	Bernard Coulie Director, Officer (President and CEO)	Open-market sale	−89,375	$1.28	$114,400
Jan 20, 2026	Kuo Minnie Officer (Chief Operating Officer)	Open-market sale	−6,917	$1.28	$8,854
Jan 23, 2025	Cheung Lily Officer (Chief Human Resource Officer)	Grant or award	+25,875	—	—
Jan 23, 2025	Ouimette Mike Officer (General Counsel & Corp. Sec'y)	Grant or award	+35,000	—	—
Jan 23, 2025	Hull Hans Officer (Chief Business Officer)	Grant or award	+40,150	—	—
Jan 23, 2025	Lefebvre Eric Officer (Chief Medical Officer)	Grant or award	+45,650	—	—
Jan 23, 2025	Cummings Keith Lamont Officer (Chief Financial Officer)	Grant or award	+56,650	—	—
Jan 23, 2025	Bernard Coulie Director, Officer (President and CEO)	Grant or award	+162,500	—	—
Jan 22, 2025	Ouimette Mike Officer (General Counsel & Corp. Sec'y)	Open-market sale	−10,230	$10.99	$112,428
Jan 17, 2025	Bernard Coulie Director, Officer (President and CEO)	Open-market sale	−52,419	$11.20	$587,093
Jan 17, 2025	Cummings Keith Lamont Officer (Chief Financial Officer)	Open-market sale	−20,148	$11.20	$225,658
Jan 17, 2025	Hull Hans Officer (Chief Business Officer)	Open-market sale	−15,936	$11.20	$178,483
Jan 17, 2025	Lefebvre Eric Officer (Chief Medical Officer)	Open-market sale	−18,478	$11.20	$206,954

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Pliant Therapeutics Inc.

Who is the CEO of Pliant Therapeutics Inc.?

Bernard Coulie is Pliant Therapeutics Inc.'s President and CEO.

How many directors are on Pliant Therapeutics Inc.'s board?

Pliant Therapeutics Inc.'s board has 13 directors: Bernard Coulie, Darren S. Cline, David E. I. Pyott, Flavia Borellini, Gayle A. Crowell, Hoyoung Huh, John T. Curnutte, Katharine Knobil, Robert Iannone, Smital Shah and 3 others.

Are Pliant Therapeutics Inc. insiders buying or selling shares?

Over the last 12 months, Pliant Therapeutics Inc. insiders made no open-market purchases and sold $163,620 of shares in 4 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Pliant Therapeutics Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="pliant-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.